Latest news

In Vitro Immune Cell Activation

02 / 19 / 2018

Modulation of the immune system function aiming at enhancing the responsiveness potential of immune cells is one of the current promising challenges in cancer immunotherapy. Upon activation, immune (T) cells undergo clonal expansion followed by differentiation into effectors to mediate cytotoxicity and/or cytokine release. Modulating the mechanisms underlying immune cell activation is key for the development of innovative approaches to promote immune function and tackle tumor progression.

Immunosuppressive Tumor Microenvironment In OT 4T1 Breast Tumor Model

10 / 16 / 2017

While known and validated as non-responsive to conventional immune checkpoint inhibitors, our OT syngeneic mammary tumor model, which represents an aggressive model of human breast carcinoma, is characterized by the presence of at least two types of tumor-infiltrating immunosuppressive cells – myeloid suppressive cells (MSC) and T regulatory cells (Treg). Such cell populations are known, as a result, to suppress effector immune cell responses, thereby promoting tumor immune escape and metastasis.

In Vitro Immune Cell-Mediated Killing

05 / 31 / 2017

Initiation of an anti-tumor immune response and further cancer cell elimination is a key step in cancer immunosurveillance. One of the current promising challenges in cancer immunotherapy is the potentiation of the specific attack of tumor cells by the immune system. Interestingly, in vitro immune cell killing is recognized as perhaps the most relevant functional measure to evaluate the ability of a candidate compound to promote such an effector function of immune cells.

Orthotopic Mouse Model Of Glioblastoma

02 / 14 / 2017

Glioblastoma (GBM) is the most aggressive primary brain tumor. Despite multimodal treatment strategies with surgery, radiation therapy and chemotherapy, the prognosis of GBM patients remains dismal. GBM are characterized by a high immune cells infiltration including myeloid derived suppressor cells (MDSCs), microglia or regulatory T cells (Tregs), all of them contributing to the creation of an immunosuppressive micro-environment. While manipulating the immune system to restore its anti-tumor activity have shown efficacy in many cancers, immunotherapy figures as an attractive therapeutic option for glioblastoma and several clinical trials are currently ongoing.